Gene Therapy for Bone Repair Using Human Cells: Superior Osteogenic Potential of Bone Morphogenetic Protein 2 –Transduced Mesenchymal Stem Cells Derived from Adipose Tissue Compared to Bone Marrow
Restricted accessResearch articleFirst published online April, 2018
Gene Therapy for Bone Repair Using Human Cells: Superior Osteogenic Potential of Bone Morphogenetic Protein 2 –Transduced Mesenchymal Stem Cells Derived from Adipose Tissue Compared to Bone Marrow
Ex vivo regional gene therapy strategies using animal mesenchymal stem cells genetically modified to overexpress osteoinductive growth factors have been successfully used in a variety of animal models to induce both heterotopic and orthotopic bone formation. However, in order to adapt regional gene therapy for clinical applications, it is essential to assess the osteogenic capacity of transduced human cells and choose the cell type that demonstrates the best clinical potential. Bone-marrow stem cells (BMSC) and adipose-derived stem cells (ASC) were selected in this study for in vitro evaluation, before and after transduction with a lentiviral two-step transcriptional amplification system (TSTA) overexpressing bone morphogenetic protein 2 (BMP-2; LV-TSTA-BMP-2) or green fluorescent protein (GFP; LV-TSTA-GFP). Cell growth, transduction efficiency, BMP-2 production, and osteogenic capacity were assessed. The study demonstrated that BMSC were characterized by a slower cell growth compared to ASC. Fluorescence-activated cell sorting analysis of GFP-transduced cells confirmed successful transduction with the vector and revealed an overall higher but not statistically significant transduction efficiency in ASC versus BMSC (90.2 ± 4.06% vs. 80.4 ± 8.51%, respectively; p = 0.146). Enzyme-linked immunosorbent assay confirmed abundant BMP-2 production by both cell types transduced with LV-TSTA-BMP-2, with BMP-2 production being significantly higher in ASC versus BMSC (239.5 ± 116.55 ng vs. 70.86 ± 24.7 ng; p = 0.001). Quantitative analysis of extracellular deposition of calcium (Alizarin red) and alkaline phosphatase activity showed that BMP-2-transduced cells had a higher osteogenic differentiation capacity compared to non-transduced cells. When comparing the two cell types, ASC/LV-TSTA-BMP-2 demonstrated a significantly higher mineralization potential compared to BMSC/LV-TSTA-BMP-2 7 days post transduction (p = 0.014). In conclusion, this study demonstrates that transduction with LV-TSTA-BMP-2 can significantly enhance the osteogenic potential of both human BMSC and ASC. BMP-2-treated ASC exhibited higher BMP-2 production and greater osteogenic differentiation capacity compared to BMP-2-treated BMSC. These results, along with the fact that liposuction is an easy procedure with lower donor-site morbidity compared to BM aspiration, indicate that adipose tissue might be a preferable source of MSCs to develop a regional gene therapy approach to treat difficult bone-repair scenarios.
Get full access to this article
View all access options for this article.
References
1.
BrinkerMR. Non-unions: evaluation and treatment. In: BrownerBD, LevineAM, JupiterJB, et al., eds. Skeletal Trauma: Basic Science, Management and Reconstruction. 4th ed. Philadelphia, PA: W.B. Saunders, 2009:615–707.
2.
St JohnTA, VaccaroAR, SahAP, et al.Physical and monetary costs associated with autogenous bone graft harvesting. Am J Orthop, 2003; 32:18–23.
3.
VirkMS, LiebermanJR. Biologic adjuvants for fracture healing. Arthritis Res Ther, 2012; 14:225.
4.
CarrageeEJ, HurwitzEL, WeinerBK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J, 2011; 11:471–491.
5.
PensakMJ, LiebermanJR. Gene therapy for bone regeneration. Curr Pharm Des, 2013; 19:3466–3473.
6.
LiebermanJR, DaluiskiA, StevensonS, et al.The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am, 1999; 81:905–917.
7.
LiebermanJR, LeLQ, WuL, et al.Regional gene therapy with a BMP2 producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res, 1998; 16:330–339.
8.
VirkMS, SugiyamaO, ParkSH, et al.“Same day” ex-vivo regional gene therapy: a novel strategy to enhance bone repair. Mol Ther, 2011; 19:960–968.
9.
HsuWK, SugiyamaO, ParkSH, et al.Lentiviral mediated BMP-2 gene transfer enhances healing of segmental femoral defects in rats. Bone, 2007; 40:931–938.
10.
ChangSC, ChuangHL, ChenYR, et al.Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration. Gene Ther, 2003; 10:2013–2019.
11.
ChangSC, LinTM, ChungHY, et al.Large-scale bicortical skull bone regeneration using ex vivo replication-defective adenoviral-mediated bone morphogenetic protein-2 gene-transferred bone marrow stromal cells and composite biomaterials. Neurosurgery, 2009; 65:75–81; discussion 81–83.
12.
ShenHC, PengH, UsasA, et al.Structural and functional healing of critical-size segmental bone defects by transduced muscle-derived cells expressing BMP4. J Gene Med, 2004; 6:984–991.
13.
WrightV, PengH, UsasA, et al.BMP4-expressing muscle derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. Mol Ther, 2002; 6:169–178.
14.
ShenHC, PengH, UsasA, et al.Ex vivo gene therapy-induced endochondral bone formation: comparison of muscle-derived stem cells and different subpopulations of primary muscle-derived cells. Bone, 2004; 34:982–992.
15.
YangM, MaQJ, DangGT, et al.In vitro and in vivo induction of bone formation based on ex vivo gene therapy using rat adipose-derived adult stem cells expressing BMP-7. Cytotherapy, 2005; 7:273–281.
16.
LinL, FuX, ZhangX, et al.Rat adipose-derived stromal cells expressing BMP4 induce ectopic bone formation in vitro and in vivo. Acta Pharmacol Sin, 2006; 27:1608–1615.
17.
SheynD, PelledG, ZilbermanY, et al.Nonvirally engineered porcine adipose tissue-derived stem cells: use in posterior spinal fusion. Stem Cells, 2008; 26:1056–1064.
18.
PetersonB, ZhangJ, IglesiasR, et al.Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Eng, 2005; 11:120–129.
19.
BreitbartAS, GrandeDA, MasonJM, et al.Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg, 1999; 42:488–495.
20.
SunM, TanW, WangK, et al.Effects of allogenous periosteal-derived cells transfected with adenovirus-mediated BMP-2 on repairing defects of the mandible in rabbits. J Oral Maxillofac Surg, 2013; 71:1789–1799.
21.
WangR, ZouY, YuanZ, et al.Autografts and xenografts of skin fibroblasts delivering BMP-2 effectively promote orthotopic and ectopic osteogenesis. Anat Rec (Hoboken), 2009; 292:777–786.
22.
HirataK, TsukazakiT, KadowakiA, et al.Transplantation of skin fibroblasts expressing BMP-2 promotes bone repair more effectively than those expressing Runx2. Bone, 2003; 32:502–512.
23.
PetersonB, IglesiasR, ZhangJ, et al.Genetically modified human derived bone marrow cells for posterolateral lumbar spine fusion in athymic rats. Spine, 2005; 30:283–289.
24.
MiyazakiM, ZukPA, ZouJ, et al.Comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow for ex vivo gene therapy in rat spinal fusion model. Spine, 2008; 33:863–869.
25.
HibiH, YamadaY, UedaM, et al.Alveolar cleft osteoplasty using tissue-engineered osteogenic material. Int J Oral Maxillofac Surg, 2006; 35:551–555.
26.
MesimäkiK, LindroosB, TörnwallJ, et al.Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. Int J Oral Maxillofac Surg, 2009; 38:201–209.
27.
ShayestehYS, KhojastehA, SoleimaniM, et al.Sinus augmentation using human mesenchymal stem cells loaded into a β-tricalcium phosphate/hydroxyapatite scaffold. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2008; 106:203–209.
28.
HassR, KasperC, BöhmS, et al.Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 2011; 14:9–12.
29.
FriedensteinAJ, PetrakovaKV, KurolesovaAI, et al.Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation, 1968; 14:230–247
30.
ViaAG, FrizzieroA, OlivaF. Biological properties of mesenchymal stem cells from different sources. Muscles Ligaments Tendons J, 2012; 2:154–162.
31.
LiaoHT, ChenCT. Osteogenic potential: comparison between bone marrow and adipose-derived mesenchymal stem cells. World J Stem Cells, 2014; 6:288–295.
32.
StriogaM, ViswanathanS, DarinskasA, et al.Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev, 2012; 21:2724–2752.
33.
De UgarteDA, MorizonoK, ElbarbaryA, et al.Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs, 2003; 174:101–109.
34.
ImGI, ShinYW, LeeKB. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells?. Osteoarthritis Cartilage, 2005; 13:845–853.
35.
VirkMS, ConduahA, ParkSH, et al.Influence of short-term adenoviral vector and prolonged lentiviral vector mediated bone morphogenetic protein-2 expression on the quality of bone repair in a rat femoral defect model. Bone, 2008; 42:921–931.
36.
SugiyamaO, AnDS, KungSP, et al.Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. Mol Ther, 2005; 11:390–398.
37.
FeeleyBT, ConduahAH, SugiyamaO, et al.In vivo molecular imaging of adenoviral versus lentiviral gene therapy in two bone formation models. J Orthop Res, 2006; 24:1709–1721.
38.
WangWZ, FangXH, WilliamsSJ, et al.Lidocaine-induced ASC apoptosis (tumescent vs. local anesthesia). Aesthetic Plast Surg, 2014; 38:1017–1023.
39.
ZhuM, Heydarkhan-HagvallS, HedrickM, et al.Manual isolation of adipose-derived stem cells from human lipoaspirates. J Vis Exp, 2013; e50585.
40.
ZukPA, ZhuM, MizunoH, et al.Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng, 2001; 7:211–228.
41.
HaynesworthSE, BaberMA, CaplanAI. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone, 1992; 13:69–80.
42.
IyerM, WuL, CareyM, et al.Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A, 2001; 98:14595–14600.
43.
AlaeeF, BartholomaeC, SugiyamaO, et al.Biodistribution of LV-TSTA transduced rat bone marrow cells used for “ex-vivo” regional gene therapy for bone repair. Curr Gene Ther, 2015; 15:481–491.
44.
DominiciM, Le BlancK, MuellerI, et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006; 8:315–317.
45.
GregoryCA, GunnWG, PeisterA, et al.An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem, 2004; 329:77–84.
46.
GarrisonKR, DonellS, RyderJ, et al.Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess, 2007; 11:1–150.
47.
TannouryCA, AnHS. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J, 2014; 14:552–559.
48.
WooEJ. Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures. Clin Orthop Relat Res, 2013; 471:1707–1711.
49.
CarofinoBC, LiebermanJR. Gene therapy applications for fracture-healing. J Bone Joint Surg Am, 2008; 90Suppl 1:99–110.
50.
KrebsbachPH, KuznetsovSA, SatomuraK, et al.Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts. Transplantation, 1997; 63:1059–1069.
51.
YeX, YinX, YangD, et al.Ectopic bone regeneration by human bone marrow mononucleated cells, undifferentiated and osteogenically differentiated bone marrow mesenchymal stem cells in beta-tricalcium phosphate scaffolds. Tissue Eng Part C Methods, 2012; 18:545–556.
52.
HicokKC, Du LaneyTV, ZhouYS, et al.Human adipose-derived adult stem cells produce osteoid in vivo. Tissue Eng, 2004; 10:371–380.
53.
ZongC, XueD, YuanW, et al.Reconstruction of rat calvarial defects with human mesenchymal stem cells and osteoblast-like cells in poly-lactic-co-glycolic acid scaffolds. Eur Cell Mater, 2010; 20:109–120.
LiX, YaoJ, WuL, et al.Osteogenic induction of adipose-derived stromal cells: not a requirement for bone formation in vivo. Artif Organs, 2010; 34:46–54.
WenY, JiangB, CuiJ, et al.Superior osteogenic capacity of different mesenchymal stem cells for bone tissue engineering. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013; 116:e324–332.
58.
CuomoAV, VirkM, PetriglianoF, et al.Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am, 2009; 91:1073–1083.
59.
BurasteroG, ScarfìS, FerrarisC, et al.The association of human mesenchymal stem cells with BMP-7 improves bone regeneration of critical-size segmental bone defects in athymic rats. Bone; 47:117–126.
60.
ConnollyJF, GuseR, TiedemanJ, et al.Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop Relat Res, 1991; 266:259–270.
61.
GargNK, GaurS, SharmaS. Percutaneous autogenous bone marrow grafting in 20 cases of ununited fracture. Acta Orthop Scand, 1993; 64:671–672.
62.
HernigouP, PoignardA, BeaujeanF, et al.Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am, 2005; 87:1430–1437.
63.
BougioukliS, JainA, SugiyamaO, et al.Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. Bone, 2016; 84:93–103.
64.
PensakM, HongS, DukasA, et al.The role of transduced bone marrow cells overexpressing BMP-2 in healing critical-sized defects in a mouse femur. Gene Ther, 2015; 22:467–475.
65.
EvansCH, HuardJ. Gene therapy approaches to regenerating the musculoskeletal system. Nat Rev Rheumatol, 2015; 11:234–242.
66.
IshiharaA, ShieldsKM, LitskyAS, et al.Osteogenic gene regulation and relative acceleration of healing by adenoviral-mediated transfer of human BMP-2 or −6 in equine osteotomy and ostectomy models. J Orthop Res, 2008; 26:764–771.
67.
BetzOB, BetzVM, NazarianA, et al.Delayed administration of adenoviral BMP-2 vector improves the formation of bone in osseous defects. Gene Ther, 2007; 14:1039–1044.
68.
RundleCH, MiyakoshiN, KasukawaY, et al.In vivo bone formation in fracture repair induced by direct retroviral-based gene therapy with bone morphogenetic protein-4. Bone, 2003; 32:591–601.
69.
KolkA, TischerT, KochC, et al.A novel nonviral gene delivery tool of BMP-2 for the reconstitution of critical-size bone defects in rats. J Biomed Mater Res A, 2016; 104:2441–2455.
70.
UmebayashiM, SumitaY, KawaiY, et al.Gene-activated matrix comprised of atelocollagen and plasmid DNA encoding BMP4 or Runx2 promotes rat cranial bone augmentation. Biores Open Access, 2015; 4:164–174.
71.
ItoH, KoefoedM, TiyapatanaputiP, et al.Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med, 2005; 11:291–297.
72.
YaziciC, TakahataM, ReynoldsDG, et al.Self-complementary AAV2.5-BMP2-coated femoral allografts mediated superior bone healing versus live autografts in mice with equivalent biomechanics to unfractured femur. Mol Ther, 2011; 19:1416–1425.
73.
DupontKM, BoerckelJD, StevensHY, et al.Synthetic scaffold coating with adeno-associated virus encoding BMP2 to promote endogenous bone repair. Cell Tissue Res, 2012; 347:575–588.
74.
GamradtSC, AbeN, BahamondeME, et al.Tracking expression of virally mediated BMP-2 in gene therapy for bone repair. Clin Orthop Relat Res, 2006; 450:238–245.
75.
GazitD, TurgemanG, KelleyP, et al.Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med, 1999; 1:121–133.
76.
DragooJL, LiebermanJR, LeeRS, et al.Tissue-engineered bone from BMP-2-transduced stem cells derived from human fat. Plast Reconstr Surg, 2005; 115:1665–1673.
77.
DragooJL, ChoiJY, LiebermanJR, et al.Bone induction by BMP-2 transduced stem cells derived from human fat. J Orthop Res, 2003; 21:622–629.
78.
HsuWK, WangJC, LiuNQ, et al.Stem cells from human fat as cellular delivery vehicles in an athymic rat posterolateral spine fusion model. J Bone Joint Surg Am, 2008; 90:1043–1052.
79.
WilsonJM. Adenoviruses as gene-delivery vehicles. N Engl J Med, 1996; 334:1185–1187.
80.
AslanH, ZilbermanY, ArbeliV, et al.Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng. 2006; 12:877–889.
81.
WangJ, LiJ, DengN, et al.Transfection of hBMP-2 into mesenchymal stem cells derived from human umbilical cord blood and bone marrow induces cell differentiation into chondrocytes. Minerva Med, 2014; 105:283–288.
82.
Abdul HalimNS, FakiruddinKS, AliSA, et al.A comparative study of non-viral gene delivery techniques to human adipose-derived mesenchymal stem cell. Int J Mol Sci, 2014; 15:15044–15060.
83.
LeeSJ, KangSW, DoHJ, et al.Enhancement of bone regeneration by gene delivery of BMP2/Runx2 bicistronic vector into adipose-derived stromal cells. Biomaterials, 2010; 31:5652–5659.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
